Nivolumab in melanoma: Added benefit in certain patients

Treatment-naive patients with BRAF V600 mutation-negative tumor have an advantage in overall survival, reviewers of the drug report.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1jBhXDs